Glycation, receptor-mediated cell activation and vascular complications of diabetes

Diabetes & Vascular Disease Research

Volumn 1, Issue 1, 2004, Pages 21-22

  Thornalley, Paul J ^a  

^a UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; LIGAND;

ANIMAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; EDITORIAL; HUMAN; IMMUNOLOGY; METABOLISM; VASCULAR ENDOTHELIUM;

ANIMALS; DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIGANDS; RECEPTORS, IMMUNOLOGIC;

EID: 23744497971     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2004.002     Document Type: Editorial

References (13)

1. Thornalley PJ, Battah S, Ahmed N et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003; 375: 581–592.
2. Schiekofer S, Andrassy M, Chen J et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappa B in PBMCs. Diabetes 2003; 52: 621–633.
3. Thornalley PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Molec Biol 1998; 44: 1013–1023.
4. Neeper M, Schmidt A-M, Brett J et al. Cloning and expression of a cell surface receptor for advanced glycosylation endproducts of proteins. J Biol Chem 1992; 267: 14998–15004.
5. Yonekura H, Yamamoto Y, Sakurai S et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochemical J 2003; 370: 1097–1109.
6. Yamamoto Y, Kato I, Doi T et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108: 261–268.
7. Wendt TM, Tanji N, Guo J et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123–1137.
8. Valencia JV, Weldon SC, Quinn D et al. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Ann Biochem 2004; 324: 68–78.
9. Valencia JV, Mone M, Zhang J, Weetall M, Buxton FP, Hughes TE. Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. Diabetes 2004; 53: 743–751.
10. Hofmann MA, Drury S, Fu CF et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889–901.
11. Park JS, Svetkauskaite D, He QB et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279: 7370–7377.
12. Treutiger CJ, Mullins GE, Johansson ASM et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003; 254: 375–385.
13. Medina L, Haltiwanger R. Calf thymus high mobility group proteins are nonenzymatically glycated but not significantly glycosylated. Glycobiology 1998; 8: 191–198.